MDS Anemia - EPO/GCSF Response
Identify those with MDS likely to respond to stem-cell factors.
In general, treatment with erythropoietin (EPO) may improve anemia in about 15-20% of patients with myelodysplastic syndromes (MDS). The combination of EPO and granulocyte colony-stimulating factor (GCSF) may improve response rates to ~40%. This predictive model uses two variables (serum EPO and transfusion need) to identify those who are most likely to respond to these stem-cell factors. The model was developed and validated predominantly in patients with low-risk MDS. Response is defined as a 100% reduction in RBC transfusion need or an increase in hemoglobin level by at least 1.5 g/L.
Hellstrom-Lindberg et al.
British Journal of Haematology 1997, 99 (2): 344-51
The MDS Anemia - EPO/GCSF Response calculator is created by QxMD.